Myricetin, a natural flavonoid, normalizes hyperglycemia in streptozotocin-cadmium-induced experimental diabetic nephrotoxic rats

Biomedicine and Preventive Nutrition

Volumn 2, Issue 4, 2012, Pages 246-251

  Kandasamy, Neelamegam ^a   Ashokkumar, Natarajan ^a  

^a ANNAMALAI UNIVERSITY   (India)

Author keywords

Diabetic nephrotoxicity; Myricetin; Streptozotocin cadmium

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CADMIUM CHLORIDE; CREATININE; DRINKING WATER; FLAVONOID; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MYRICETIN; NITROGEN; STREPTOZOCIN; UREA; URIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG DOSE COMPARISON; DRUG STRUCTURE; ENZYME ACTIVITY; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; INSULIN BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; STREPTOZOCIN DIABETES; TREATMENT OUTCOME; URINE VOLUME; WEIGHT REDUCTION;

RATTUS;

EID: 84869079875     PISSN: 22105239     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bionut.2012.04.003     Document Type: Article

References (41)

1. Kardesler L., Buduneli N. By koglu B, Cetinkalp S, Kutukculer N. Gingival crevicular fluid PGE2, IL-1ß, t-PA, PAI-2 levels in type 2 diabetes and relationship with periodontal disease. Clinical Biochemistry 2008, 41(10-11):863-868.
2. Aragao D.M.O., Guarize L., Lanini J., DaCosta J.C., Garcia R.M.G., Scio E. Hypoglycemic effects of Cecropia pachystachya in normal and alloxan-induced diabetic rats. J Ethnopharmacol 2010, 128:629-633.
3. Fowler M.J. Microvascular and macrovascular complications of diabetes. Clin Diab 2008, 26:77-82.
4. Balakumar P., Chakkarwar V.A., Kumar V., Jain A., Reddy J., Singh M. Experimental models for nephropathy. J Renin Angiotensin Aldosterone Syst 2008, 9:189-195.
5. Huang Y.H., Wang H.T., Zhu Q.Z., Zhang H., Shen W., Wang Y. Combination therapy with losartan and fosinopril for early diabetic nephropathy. Di Yi Jun Yi Da Xue Xue Bao 2004, 23:963-965.
6. Schrijvers B.F., Vriese A.S.D., Flyvbjerg A. Fromhyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endo Rev 2004, 25:971-1010.
7. Satarug S., Moore M.R. Adverse health effects of chronic exposure to low-level Cadmium in foodstuffs and cigarette smoke. Environ Health Persp 2004, 112:1099-1103.
8. Jin T., Nordberg G., Sehlin J., Wallin H., Sandberg S. The susceptibility to nephrotoxicity of Streptozotocin-induced diabetic rats subchronically exposed to Cadmium chloride in drinking water. Toxicology 1999, 142:69-75.
9. Nordberg G.F. Application of the 'critical effect' and 'critical concentration' concept to human risk assessment for Cadmium. Cadmium in the human environment: toxicity carcinogenicity 1992, 118. IARC, Lyon, France, 1-12.
10. Moller D.E. New drug targets for type 2 diabetes and the metabolicsyndrome. Nature 2001, 414821-414827.
11. Asgary S., Naderi G.A., SarrafZadegan N., Vakili R. The inhibitoryeffects of pure flavonoids on in vitro protein glycosylation. J Herb Pharmacother 2002, 2:47-55.
12. Ajay M., Mustafa M.R. Chronic treatment with flavonoids preventsendothelial dysfunction in spontaneously hypertensive rat aorta. J Cardiovasc Pharmacol 2005, 46:36-40.
13. Miean K.H., Mohamed S. Flavonoid (Myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J of Agri and Food Chem 2001, 49(6):3106-3112.
14. Harnly J.M., Doherty R.F., Beecher G.R., Holden J.M., Haytowitz D.B., Bhagwat S., et al. Flavonoids content of U.S. fruits, vegetables, and nuts. J Agri Food Chem 2006, 54(26):9966-9977.
15. Ong K.C., Khoo H.E. Biological effects of myricetin. Gen Pharmacol 1997, 29:121-126.
16. Knekt P., Kumpulainen J., Jarvinen R., Rissanen H., Heliovaara M., Reunanen A., et al. Flavonoid intake andrisk of chronic diseases. Am J Clin Nutr 2002, 76:560-568.
17. Ong K.C., Khoo H.E. Insulinomimetic effects of Myricetin on lipogenesisand glucose transport in rat adipocytes but not glucose transporttranslocation. Biochem Pharmacol 1996, 51:423-429.
18. Siddique O., Sun Y., Lin J.C., Chien Y.W. Facilitated transdermal transport of insulin. J Pharmaceutic Sci 1987, 76:341-345.
19. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 1969, 6:24-27.
20. Reinhold J.G. Manual determination of serum total protein, albumin and globulin fractions by Biuret method. Standard Methods in Clinical Chemistry 1953, Academic Press, New York, 88. M. Reiner (Ed.).
21. Fawcett J.K., Scott J.E. A rapid and precise method for the determination of urea. J Clin Path 1960, 3:156-159.
22. Caraway W.T. Determination of uric acid in serum by carbonate method. Am J Clin Path 1955, 25:840-845.
23. Tietz N.W. Fundamentals of Clinical Chemistry 1987, WB Saunders Company, Philadelphia, p. 638.
24. Jaffe M. Concerning the precipitate produced in normal urine by picric acid and a new reaction of creatinine. Z Physiol Chem 1886, 10:391-400.
25. Diawara M.M., Litt J.S., Unis D., Alfonso N., Martinez L., Crock J.G., et al. Arsenic, Cadmium, lead, and mercury in surface soils, Pueblo, Colorado: implications for population health risk. Environ Geochem Health 2006, 28:297-315.
26. Cackovic M., Kalinic N., Vadjic V., Pehnec G. Heavy metals and acidic components in total deposited matter in Sibenik and National Park Kornati Croatia. Arch Environ Contam Toxicol 2009, 56:12-20.
27. Prozialeck W.C., Vaidya V.S., Liu J., Waalkes M.P., Edwards J.R., Lamar P.C., et al. Kidney injury molecule-1 is an early biomarker of Cadmium nephrotoxicity. Kidney Int 2007, 72:985-993.
28. Jarup L. Cadmium overload and toxicity. Nephrol Dial Transplant 2002, 17:35-39.
29. Kawada T., Koyama H., Suzuki S. Cadmium NAG activity, and β2-microglobulin in the urine of Cadmium pigment workers. Br J Ind Med 1989, 46:52-55.
30. Roels H., Bernard A.M., Cardenas A., Buchet J.P., Lauwerys R.R., Hotter G., et al. Markers of early renal changes induced by industrial pollutants. Application to workers exposed to Cadmium. Br J Ind Med 1993, 50:37-48.
31. Jarup L., Persson B., Elinder C.G. Decreased glomerular filtration rate in solderers exposed to Cadmium. Occup Environ Med 1995, 52:818-822.
32. Jin T., Nordberg G., Sehlin J., Leffler P., Wu J. The susceptibility of spontaneously diabetic mice to Cadmium metallothionein nephrotoxicity. Toxicology 1994, 89:81-90.
33. Jin T., Frankel B.J. Cadmium-metallothionein nephrotoxicity is increased in genetically diabetic as compared with normal Chinese hamsters. Pharmacol Toxicol 1996, 79:105-108.
34. Al-Shamaony L., Al-Khazraji S.M., Twaij H.A. Hypoglycemic effect of Artemisia herba alba II. Effect of a valuable extract on some blood parameters in diabe tic rats. J Ethnopharmacol 1994, 43:167-171.
35. Szkudelski T., Szkudeslka K. Streptozotoci n induces lypolysis in rat adipocytes in vitro. Physiology Resh 2002, 51:255-259.
36. Chen V., Ianuzzo C.D. Dosage effect of Streptozotocin on rat tissue enzyme activities and glycogen concentration. Can J Physiol Pharmacol 1982, 60:1251-1256.
37. Roden M., Bernroider E. Hepatic glucose metabolism in humans-its role in health and disease. Best Pract Res Clin Endocrinol Metabol 2003, 17:365-383.
38. Pari L., Ashok Kumar N. Hepatoprotective activity of moringa oleifera on antitubercular drug induced liver damage in rats. J Med Food 2002, 5:171-177.
39. Mahboob M., Rahman M.F., Grover P. Serum lipid peroxidation and anti-oxidant enzyme levels in male and female diabetic patients. Singapore Med J 1982, 46:322-324.
40. Madinov I.V., Balabolkin M.I., Markov D.S. Main causes of hyperuricemia in diabetes mellitus. Ter Arkh 2000, 72:55-58.
41. Parving H.H., Mauer M., Ritz E. Diabetic nephropathy. Brenner and Rector's the Kidney 2004, Philadelphia Saunders, 1777-818. 7th ed. B.M. Brenner (Ed.).